ISRG Intuitive Surgical
A strong surgical-robotics franchise, but even generous drivers leave the price ahead of value.
The story
Intuitive Surgical is the dominant franchise in robotic-assisted surgery. Its moat comes from an installed base of more than 10,000 da Vinci systems, surgeon training lock-in, decades of clinical data and a razor/blade model where about 85% of revenue recurs from instruments, accessories and service. The company is in late high growth: procedure volume is still growing in the mid-teens as da Vinci 5 rolls out, Ion expands and the business pushes into general surgery and international markets. Competitors such as Medtronic Hugo and J&J Ottava are finally arriving, which will slowly squeeze pricing and share at the margin rather than break the franchise.
Procedure growth of 15-17% plus da Vinci 5 upgrades support about 15.5% growth in the first year, fading over a 12-year horizon that this durable moat justifies. Margins rise modestly from 32% to 35% through recurring revenue leverage, but competition and tariffs on instruments cap them below the old 38% peak. Sales-to-capital is set above the reported 0.65 because that figure is inflated by excess cash and by leased-system assets carried on the balance sheet; the marginal capital needed per dollar of new sales is lower.
Value drivers
| Revenue growth (Y1) | 15.5% |
| Terminal growth | 4.0% |
| Forecast horizon | 12y |
| Target operating margin | 35.0% |
| Years to target margin | 5 |
| Sales-to-capital | 1.20 |
| Beta | 1.00 |
| Failure probability | 0.5% |
| Cost of capital (WACC) | 9.4% |
| Terminal WACC | 9.4% |
Valuation bridge
| PV of explicit FCFF | 35.98B |
| PV of terminal value | 51.90B |
| Equity value | 90.67B |
| ÷ shares → per share | $256.64 |
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 13.37B | 15.5% | 32.8% | 3.81B | 1.50B | 2.31B | 2.12B |
| 2 | 15.31B | 14.5% | 33.4% | 4.43B | 1.61B | 2.82B | 2.36B |
| 3 | 17.36B | 13.4% | 33.9% | 5.11B | 1.71B | 3.40B | 2.60B |
| 4 | 19.50B | 12.4% | 34.5% | 5.84B | 1.79B | 4.05B | 2.83B |
| 5 | 21.71B | 11.3% | 35.0% | 6.60B | 1.84B | 4.76B | 3.04B |
| 6 | 23.94B | 10.3% | 35.0% | 7.28B | 1.86B | 5.42B | 3.16B |
| 7 | 26.15B | 9.2% | 35.0% | 7.95B | 1.84B | 6.11B | 3.26B |
| 8 | 28.29B | 8.2% | 35.0% | 8.60B | 1.78B | 6.82B | 3.32B |
| 9 | 30.31B | 7.1% | 35.0% | 9.22B | 1.68B | 7.53B | 3.36B |
| 10 | 32.16B | 6.1% | 35.0% | 9.78B | 1.54B | 8.24B | 3.36B |
| 11 | 33.78B | 5.0% | 35.0% | 10.27B | 1.35B | 8.92B | 3.32B |
| 12 | 35.13B | 4.0% | 35.0% | 10.68B | 1.13B | 9.55B | 3.25B |
Key risks
- Medtronic Hugo, J&J Ottava and Chinese competitors compress system pricing and take share in cost-sensitive markets
- Tariffs and hospital capital-budget pressure slow system placements and da Vinci 5 upgrade cycles
- GLP-1 drugs reduce bariatric and some metabolic procedure volumes, and the valuation (about 13x sales) leaves no room for disappointment
Catalysts
- da Vinci 5 full launch and new indications (cardiac, expanded general surgery) driving instrument use per procedure
- International expansion (Japan, Europe, India) and Ion lung-biopsy adoption keeping procedure growth in the mid-teens